BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, September 26, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Irreversible covalent CDK7 inhibitor exhibits potent occupancy, antitumor activity in vivo
To read the full story,
subscribe
or
sign in
.
Cancer
Irreversible covalent CDK7 inhibitor exhibits potent occupancy, antitumor activity in vivo
Sep. 20, 2024
No Comments
Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of RNA polymerase II (RNAPII).
BioWorld Science
Conferences
Cancer